Conference on Forced Degradation Strategies

Venue: BSG Conference Centre

Location: London, United Kingdom

Event Date/Time: Jun 03, 2010 End Date/Time: Jun 04, 2010
Registration Date: Jun 03, 2010
Early Registration Date: Jun 03, 2010
Report as Spam


Key Speakers

Dr David Elder, Director - SCINOVO (PCD), GSK
Philip MacFaul, Associate Principal Scientist, AstraZeneca
Dr C Jane Robinson, Principal Scientist, National Institute for Biological Standards & Control (NIBSC)
Dr Dagmar Mohr, Group Head - Analytical R&D and QC Biotech Products, F. Hoffmann-La Roche
Michael Becker, Head - Marketing and Product Manager, Solvias
Dr Paul Dalby, Dept of Biochemical Engineering, University College London
Chris Hazelby, General Manager, Atlas Material Testing
Mark Benger, Senior Manager - Physical and Analytical Chemistry, Aptuit
James Hurst, Head - Analytical Development, Almac Pharma Services

Conference Introduction
Forced Degradation Strategies
3rd - 4th June 2010, London, UK

Effective forced degradation strategies assessing the stability in early phase of drug development is vital for the long term success of any drug. Analytical techniques are very sensitive to support very low levels of detection (LOD) and quantitation (LOQ). In recent years, analytical technologies have advanced so much that the detection of impurities at very low levels has become significantly less complex, though it still poses numerous challenges.

Forced Degradation Strategies conference addresses the latest challenges and up-to-date advances to develop accurate forced degradation testing for accelerated drug development. From formulation to existing products, this 2 day conference will provide hottest information in the field of stress testing and forced degradation. Gain access to insights, case studies and techniques in implementing cost effective degradation and analytical validation methods across biologics, API and small molecules.
Our forced degradation strategies conference is a great forum to maximise knowledge and gain commercial acumen for stable drug development. Get started with latest technologies and software advances through our key note presentations and discussions shared by industry champions at this ground-breaking event.

Learn, discuss and gain knowledge on:
• Forced degradation studies: Groundwork and practical aspects
• Forced degradation concepts for small and big molecules
• Drug degradation chemistry within drug discovery
• Bioassays for assessing degradation
• Monitoring and evaluation of single amino acid modifications of therapeutic monoclonal antibodies
• Pre-formulation of proteins by high-throughput techniques
• Rapid and robust excipient selection during formulation development
• Comparing two different excipient screening approaches for the same drug
• Integrated approach to detect and quantify genotoxic impurities in APIs
• Quality by Design (QbD) application to GTI control strategy
• In silico prediction of forced degradation
• Regulatory perspectives on drug degradation and stress testing

Who should attend?

Heads of Department, Directors, Managers and Scientists in:
• Analytical Development
• Analytical Chemistry
• Pre-Formulation
• Formulation
• Solid State Chemistry
• Chromatography
• Crystallisation
• API Development
• QbD
• Validation
• Stability Testing
• Pharmacokinetics
• Toxicokinetics
• R&D
• Regulatory Affairs
• Quality Control
• Quality Assurance


BSG House, London, UK
United Kingdom